Allergan plc, (global pharmaceutical company), today announced the official launch of TrueTear®, the first and only FDA-cleared device developed to temporarily increase tear production during neurostimulation in adult patients.
Allergan describes TrueTear®, as a handheld neurostimulation device with disposable tips that is inserted into the nasal cavity to induce the production of natural tears, is a novel and innovative approach for those patients with inadequate tear production. In two clinical trials, TrueTear® was shown to be safe and effective for temporarily increasing tear production in adult patients.
The neurostimulation device will be officially launched during the 2018 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators annual meetings being held April 13-17 in Washington, DC.
“TrueTear® is the latest in a long line of innovations that have helped make Allergan a leading global eye care company. We are excited to add this drug-free, drop-free treatment option for adult patients with inadequate tear production to our current portfolio. This milestone truly represents our company’s ongoing commitment to developing eye care products that help improve the lives of patients,” said Jag Dosanjh, Senior Vice President, US Eye Care. “For more than 70 years, Allergan has remained focused on delivering the most innovative eye care products in the industry. TrueTear® continues the proud heritage of our foundational philosophy: to bring innovative treatments to patients around the world.”
“As seen in clinical trials and in my own post-approval experience treating patients, TrueTear® provides tiny pulses of energy within the nasal cavity to create tears and may be appropriate for most patients with inadequate tear production,” said John Sheppard, M.D., M.M. Sc., F.A.C.S., Professor of Ophthalmology, Eastern Virginia Medical School and President of Virginia Eye Consultants in Norfolk, Virginia. “TrueTear® is the first device of its kind, providing a temporary increase in tear production with neurostimulation, thereby returning the ocular surface to a more normal physiologic state without prescribing drops or surgery.”
As a leader in eye care, Allergan has discovered, developed, and delivered some of the most innovative products in the industry over the last 70 years. Allergan has launched over 125 eye care products and invested billions of dollars in new treatments for the most prevalent eye conditions including glaucoma, ocular surface disease, and retinal diseases such as diabetic macular edema and retinal vein occlusion. Our eye care pipeline includes 13 additional agents for multiple ocular conditions.
Our commitment to the well-being of patients is also reflected in philanthropy. Allergan and The Allergan Foundation support more than 150 organizations around the world working to improve lives and communities. We remain steadfast in helping eye care providers deliver the best in patient care through innovative products and outreach programs.
The TrueTear® device is a prescription-only device. Adult patients with dry eye should consult with their eye care professional about TrueTear®.